Log in

NASDAQ:GLYCGlycoMimetics Stock Price, Forecast & News

$2.95
+0.08 (+2.79 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.90
Now: $2.95
$3.05
50-Day Range
$2.41
MA: $2.83
$3.18
52-Week Range
$1.82
Now: $2.95
$13.44
Volume418,891 shs
Average Volume312,628 shs
Market Capitalization$128.56 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Read More
GlycoMimetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.12 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.56 per share

Profitability

Net Income$-57,890,000.00

Miscellaneous

Employees50
Market Cap$128.56 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

How has GlycoMimetics' stock been impacted by COVID-19 (Coronavirus)?

GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GLYC stock has increased by 0.3% and is now trading at $2.95. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GlycoMimetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GlycoMimetics.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for GlycoMimetics.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) announced its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.12. The biotechnology company earned $9 million during the quarter. View GlycoMimetics' earnings history.

What price target have analysts set for GLYC?

6 Wall Street analysts have issued 12-month price objectives for GlycoMimetics' shares. Their forecasts range from $5.00 to $16.00. On average, they anticipate GlycoMimetics' share price to reach $8.75 in the next year. This suggests a possible upside of 196.6% from the stock's current price. View analysts' price targets for GlycoMimetics.

Has GlycoMimetics been receiving favorable news coverage?

News coverage about GLYC stock has been trending somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlycoMimetics earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutGlycoMimetics.

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the following people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 60)
  • Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
  • Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
  • Mr. Henry Flanner, VP of Technical Operations

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (11.09%), BlackRock Inc. (6.36%), Invesco Ltd. (5.48%), State Street Corp (1.43%), Geode Capital Management LLC (1.19%) and Morgan Stanley (1.10%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius and John L Magnani. View institutional ownership trends for GlycoMimetics.

Which major investors are selling GlycoMimetics stock?

GLYC stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Redmile Group LLC, AXA, BlackRock Inc., Parametric Portfolio Associates LLC, Athanor Capital LP, UBS Group AG, and State Street Corp. View insider buying and selling activity for GlycoMimetics.

Which major investors are buying GlycoMimetics stock?

GLYC stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Federated Hermes Inc., Morgan Stanley, Two Sigma Advisers LP, Two Sigma Investments LP, Wells Fargo & Company MN, AQR Capital Management LLC, and Geode Capital Management LLC. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il, and Daniel M Junius. View insider buying and selling activity for GlycoMimetics.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $2.95.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $128.56 million. The biotechnology company earns $-57,890,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is www.glycomimetics.com.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.